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Sir,
We read with great interest the paper by Sassa et al. published
in the European Journal of Nuclear Medicine and Molecular
Imaging entitled BEvaluation of 11C-choline PET/CT for pri-
mary diagnosis and staging of urothelial carcinoma of the
upper urinary tract: a pilot study^ [1]. Nuclear medicine mo-
dalities are able to detect metabolic changes in neoplastic
cells. This has been demonstrated in many tumours, but the
role of FDG and 11C-choline PET/CT in the evaluation of
upper urinary tract urothelial carcinoma (UUT-UC) is still
undefined. Thus, we are grateful to the authors for the inter-
esting and innovative study. To date, few data are available
regarding the staging of UUT-UC, and unfortunately the level
of evidence is poor, especially for lymph node evaluation.
Sassa et al. [1] in their prospective study enrolling 16 pa-
tients found a sensitivity and specificity in lymph node inva-
sion of 91.6 % and 50 %, respectively. Conversely, Asai et al.
[2] in their retrospective study in 50 patients found a sensitiv-
ity and specificity of 83 % and 100 %, respectively, using
FDG as a metabolic radiopharmaceutical agent. Beyond the
limitations of these studies, it is reasonable to imagine that
PET/CT could play a role in the staging of UUT-UC and in
planning lymph node dissection (LND). The best LND
template is still unknown and it is limited to staging
only [3]. However, some limitations and controversies have
arisen. Firstly, LND in transitional cancer of the bladder is
used for both tumour staging and cancer control. This is in
contrast to what is known on UUT-UC, even though UUT-UC
has the same histotype of the lower urinary tract. Secondly,
CTurography has the highest diagnostic accuracy in UUT-UC
[4–6], but its performance in detecting suspicious lymph node
metastases has not been fully evaluated. Although the pres-
ence of enlarged lymph nodes is highly predictive of metasta-
sis [7], the anatomical site for the LND has not been clearly
defined and consequently the effective accuracy of imaging is
doubtful. Thirdly, few models that are able to accurately pre-
dict lymph node involvement in locally advanced cancer have
been described [8]. Fourthly, it seems that the number of re-
moved lymph nodes has a lower impact on patient survival
than the LND template [9]. Lastly, CT urography andMRI are
unable to discriminate patients with a high risk of lymph node
metastases from those with a low/intermediate risk, and thus
are unable to guide LND planning.
The promising results of 11C-choline PET/CT in the prima-
ry diagnosis and staging of UUT-UC raises interesting ques-
tions that only further studies will answer:
1. Can we use radiolabelled choline PET/CT to better strat-
ify patients and to understand the best LND template?
2. Can PET/CT change the indication to conservative sur-
gery (endourological treatment) from more aggressive
surgery (nephroureterectomy with lymphadenectomy)?
3. Do coregistration of CT urography and PET/CT data al-
low better staging of primary tumour and lymph node
metastases?
Moreover, Asai et al. [2] found that using a dedicated pro-
tocol for patient preparation, hypermetabolic lesions could be
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easily detected and UUT-UC precisely located by FDG PET/
CT in spite of the difficulties posed by urinary excretion of the
tracer. Therefore, FDG PET/CT could be considered an alter-
native diagnostic strategy in this setting.
In conclusion, we believe that Sassa et al. [1] have raised
more questions than answers. Further studies are needed in
this tumour that is close to bladder cancer but at the same time
completely different and unclear.
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